polyglutamine aggregation inhibitor

The polyglutamine aggregation inhibitor developed by ITL Pharmaceuticals (Innovative Therapies Ltd) is an experimental therapeutic candidate that was in IND-enabling development for the treatment of Huntington's Disease (HD) and other polyglutamine (polyQ) expansion disorders. The drug's mechanism of action involves targeting and inhibiting the aggregation of proteins containing expanded polyglutamine tracts, such as the mutant huntingtin protein. By preventing the formation of toxic intracellular aggregates and inclusions, the therapy aims to mitigate neurodegeneration and preserve neuronal function. ITL Pharmaceuticals' pipeline in the early 2010s highlighted this program as a lead candidate for HD. Additionally, the company maintained a separate line of research reagents for cell culture applications, including poly-lysine coatings, which were used in laboratory models of protein misfolding.

Other names

PolyGlutamine-ITL Pharmaceuticals-Cell Culture (research reagent)